Shares of Bruker Co. (NASDAQ:BRKR – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $80.82.
Several equities research analysts have weighed in on BRKR shares. Barclays initiated coverage on Bruker in a research report on Tuesday. They issued an “overweight” rating and a $75.00 target price on the stock. Wolfe Research cut shares of Bruker from an “outperform” rating to a “peer perform” rating in a report on Monday, September 30th. Citigroup reduced their target price on shares of Bruker from $95.00 to $80.00 and set a “buy” rating for the company in a research note on Wednesday, July 10th. TD Cowen dropped their price target on shares of Bruker from $74.00 to $72.00 and set a “hold” rating on the stock in a research note on Wednesday, August 7th. Finally, The Goldman Sachs Group reduced their price objective on Bruker from $72.00 to $60.00 and set a “sell” rating for the company in a research report on Tuesday, July 9th.
Institutional Trading of Bruker
Bruker Trading Down 2.9 %
NASDAQ BRKR opened at $61.27 on Monday. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.75 and a current ratio of 1.65. Bruker has a one year low of $53.79 and a one year high of $94.86. The company has a 50-day simple moving average of $65.15 and a 200-day simple moving average of $69.44. The firm has a market capitalization of $8.90 billion, a PE ratio of 22.28, a price-to-earnings-growth ratio of 2.52 and a beta of 1.18.
Bruker (NASDAQ:BRKR – Get Free Report) last issued its earnings results on Tuesday, August 6th. The medical research company reported $0.52 EPS for the quarter, meeting analysts’ consensus estimates of $0.52. The company had revenue of $800.70 million during the quarter, compared to the consensus estimate of $799.44 million. Bruker had a return on equity of 24.92% and a net margin of 11.29%. Bruker’s quarterly revenue was up 17.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.50 earnings per share. On average, equities analysts forecast that Bruker will post 2.61 earnings per share for the current year.
Bruker Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Monday, September 16th. Investors of record on Monday, September 2nd were issued a dividend of $0.05 per share. The ex-dividend date was Friday, August 30th. This represents a $0.20 annualized dividend and a yield of 0.33%. Bruker’s payout ratio is 7.27%.
About Bruker
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Further Reading
- Five stocks we like better than Bruker
- What Do S&P 500 Stocks Tell Investors About the Market?
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- How to Invest in the FAANG Stocks
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- What is the Dogs of the Dow Strategy? Overview and Examples
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.